• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

New Biomarkers for Atherothrombosis in Antiphospholipid Syndrome: Genomics and Epigenetics Approaches
Conclusions In recent years, there have been many advances in the understanding of the molecular basis for vascular involvement in APS, but many areas need to be further investigated, in particular the association between altered genetic/epigenetic profiles, autoantibodies and clinical manifestations, and the effectiveness of new therapeutic strategies. It would be interesting to apply next generation sequencing technologies like RNA-Seq along with GWAS to screen both, the gene profile and the whole transcriptome of large cohorts of primary APS patients, in order to reveal the mutations/polymorphisms, post-transcriptiona...
Source: Frontiers in Immunology - April 15, 2019 Category: Allergy & Immunology Source Type: research

Evidence does not back primary CVD prevention with statins
Evidence does not support the widespread use of statins in healthy older people to prevent heart disease and stroke, according to the authors of a new Spanish study.
Source: Nursing Times - September 7, 2018 Category: Nursing Source Type: news

Evidence Doesn ' t Support Statin Use in Healthy Seniors
THURSDAY, Sept. 6, 2018 -- There is no evidence to support the widespread use of cholesterol-lowering statin drugs to prevent heart disease and stroke in old and very old people, Spanish researchers say. For the new study, the investigators analyzed...
Source: Drugs.com - Daily MedNews - September 6, 2018 Category: General Medicine Source Type: news

Cost-effectiveness and Budget Impact of Treatment with Evolocumab Versus Statins and Ezetimibe for Hypercholesterolemia in Spain
ConclusionsTreatment with evolocumab is associated with a lower frequency of cardiovascular events, but is inefficient for patients suitable to receive this drug in the Spanish National Health System.ResumenIntroducción y objetivosAnalizar la razón de coste-efectividad y el impacto presupuestario del tratamiento con evolocumab (inhibidor de la PCSK9) para pacientes en prevención secundaria en el Sistema Nacional de Salud español.MétodosSe realizaron, desde la perspectiva del sistema sanitario público, análisis de impacto presupuestario, modelos de árbol de decisión y Markov, basándose en el único ensayo clínico...
Source: Revista Espanola de Cardiologia - July 10, 2018 Category: Cardiology Source Type: research